Health Condition 1: J309- Allergic rhinitis, unspecified
Conditions
Interventions
Intervention1: 27.5 micrograms of Fluticasone Furoate and 50mcg of Oxymetazoline Hydrochloride nasal spray: Two spray actuations (27.5 micrograms of Fluticasone Furoate and 50mcg of Oxymetazoline Hydr
Sponsors
Zydus Healthcare Limited
Eligibility
Inclusion criteria
Inclusion criteria: Patients with a clinical diagnosis of allergic rhinitis or any nasal condition where-in the treating physician deems the patient suitable to receive treatment with a combination of intranasal corticosteroid and nasal decongestant will be included in the study. No further inclusion or exclusion criteria were defined beyond the information given in the package insert.
Exclusion criteria
Exclusion criteria: No further inclusion or exclusion criteria were defined beyond the information given in the package insert.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All the patients will undergo a thorough clinical evaluation as per standard / routine hospital protocol for management of allergic rhinitis at baseline and at each follow-up. Symptom scores of the last day of treatment to be compared with that of the first day of treatment for the same patient to assess for rebound congestion.Timepoint: Baseline - Day 0 First follow up - before Day 28 Second follow up - before or on Day 28 | — |
Secondary
| Measure | Time frame |
|---|---|
| NilTimepoint: Nil | — |
Countries
India
Contacts
Public ContactDr Ashok Jaiswal
Zydus Healthcare Limited
Outcome results
None listed